Myriad Genetics Inc - Company Profile
Powered by 
All the sales intelligence you need on Myriad Genetics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Myriad Genetics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Myriad Genetics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Myriad Genetics Inc (Myriad) is a molecular diagnostic testing and medicine company. The company develops and offers molecular tests that assess disease risk, guide treatment decisions, and enhance patient care in areas such as cancer risk, family planning, mental health, oncology, prenatal care, primary care, and urology. Its major products include genetic screens and tests, such as carrier screens, fetal sex determination, germline testing, prenatal screens, pharmacogenomic testing, and tumor testing. The company's products are used by healthcare providers to detect, treat, and prevent diseases, serving patients across various medical specialties. It operates manufacturing facilities in the US. Myriad is headquartered in Salt Lake City, Utah, the US.
Headquarters
United States of America
Address
322 North 2200 West, Salt Lake, Utah, 84116
Website
www.myriad.com
Telephone
1 801 5843600
No of Employees
2,700
Industry
Medical Equipment
Ticker Symbol & Exchange
MYGN (NASD)
Revenue (2024)
$824.5M
-1.6%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-187.4%
(2024 vs 2023)
Market Cap*
$576.1M
Net Profit Margin (2024)
XYZ
-192.0%
(2024 vs 2023)
* As of and is in US$
Myriad Genetics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Tests for: | BRACAnalysis |
| Fetal Sex | Colaris |
| Germline | MyRisk |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Regulatory Approval | In April, the company secured approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) to use the MyChoice Test for prostate cancer patients as a companion diagnostic for Lynparza (olaparib). |
| 2026 | Regulatory Approval | In March, the company secured FDA approval for its MyChoice CDx Test as the companion diagnostic for Zejula in the US. |
| 2025 | Contracts/Agreements | In November, the company, Clairity and MagView collaborated to improve identification of women at high risk for breast cancer by enhancing risk assessment workflows. |
Competitor Comparison
| Key Parameters | Myriad Genetics Inc | Labcorp Holdings Inc | Quest Diagnostics Inc | Natera Inc | Tempus AI Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Salt Lake | Burlington | Secaucus | Austin | Chicago |
| State/Province | Utah | North Carolina | New Jersey | Texas | Illinois |
| No. of Employees | 2,700 | 71,000 | 46,000 | 6,135 | 3,800 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Samraat S. Raha | Chief Executive Officer; Director; President | Executive Board | 2025 | 54 |
| Benjamin R. Wheeler | Chief Financial Officer | Senior Management | 2025 | 42 |
| Mark S. Verratti | Chief Operating Officer | Senior Management | 2025 | 57 |
| Jennifer Fox | Chief Legal Officer | Senior Management | 2024 | 53 |
| Shereen Solaiman | Chief People Officer | Senior Management | 2023 | 53 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer